NCT01023880 - Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

January 31, 2013

Conditions

Multiple Myeloma

Interventions

DRUG

CEP-18770

CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.

Trial Locations (13)

Unknown

Mayo Clinic- Scottsdale, Scottsdale

University of Arkansas for Medical Sciences, Little Rock

Stanford Heme Group, Palo Alto

University of California, San Francisco, San Francisco

Washington Cancer Institute, Washington D.C.

Northwestern University Medical School, Chicago

Henry Ford Health System Protocol Review Committee, Detroit

Sparrow Regional Cancer Center, Lansing

Washington University School of Medicine, St Louis

John Theurer Cancer Center, Hackensack

Duke University Medical Center, Durham

University of Pennsylvania, Philadelphia

Medical College of Wisconsin, Milwaukee